Table 4. Use of RSV prevention products by age group in jurisdictions with (Queensland and Western Australia) and without population-based nirsevimab programmes, Australia, 2024 .

Age and case-control status		Jurisdiction
		New South Wales				Victoria				Queenslanda				Western Australiaa				South Australia				Tasmania				Northern Territory				Australian Capital Territory				Total
		Imm		Unimm		Imm		Unimm		Imm		Unimm		Imm		Unimm		Imm		Unimm		Imm		Unimm		Imm		Unimm		Imm		Unimm		Imm		Unimm
Age	Group	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
0–11 months	Cases	1	0.5	203	99.5	0	0	488	100	10	8.0	115	92.0	27	20.2	107	79.8	2	1.1	187	98.9	0	0	18	100	0	0	50	100	0	0	0	0	40	3.3	1,168	96.7
	Controls	2	9.1	20	90.9	8	5.8	131	94.2	21	26.2	59	73.8	37	48.1	40	51.9	2	2.5	77	97.5	0	0	0	0	3	6.7	42	93.3	0	0	0	0	73	16.5	369	83.5
12–23 months	Cases	0	0	108	100	1	0.4	255	99.6	5	4.3	112	95.7	7	3.5	193	96.5	0	0	99	100	0	0	11	100	0	0	29	100	0	0	0	0	13	1.6	807	98.4
	Controls	1	7.7	12	92.3	2	2.7	72	97.3	3	8.3	33	91.7	4	12.9	27	87.1	0	0	33	100	0	0	0	0	0	0	34	100	0	0	0	0	10	4.5	211	95.5
≥ 60 years	Cases	0	0	0	0	2	5.3	36	94.7	0	0	52	100	0	0	56	100	1	3.0	32	97.0	0	0	20	100	0	0	3	100	0	0	22	100	3	1.3	221	98.7
	Controls	1	2.8	35	97.2	3	1.9	154	98.1	1	0.4	226	99.6	0	0	74	100	0	0	40	100	0	0	20	100	0	0	20	100	0	0	53	100	5	0.8	622	99.2

Imm: immunised; RSV: respiratory syncytial virus; Unimm: unimmunised.

^a Jurisdictions with population-based nirsevimab programmes are indicated in grey.

Cases and controls aged 0–11 months in Queensland and WA: n = 416 versus other jurisdictions: n = 1,234. Cases and controls aged 12–23 months in Queensland and WA: n = 384 versus other jurisdictions: n = 657. Cases and controls aged ≥ 60 in all jurisdictions: n = 851.

No mothers of infant cases or controls were reported to have received the maternal RSVpreF vaccine.